US FDA approved new drug that that contains active pharmaceutical ingredient Benznidazole for the treatment of Chagas disease in pediatric patients having age 2 to 12 years. This is first kind of therapy approved by US FDA for the treatment of chagas in pediatric patients.
Chagas disease is also termed as American trypanosomiasis is a kind of rare tropical parasitic disease causes by parasite known as trypanosoma cruzi. Insects or bugs like triatominae are carriers of such parasite and when they bite or suck blood from human body this parasite gets enter into blood stream. Commonly observed symptoms are fever, swelling and enlargement of lymph nodes, body pain, headache and swelling in extremities.
This parasite may also cause infection in animals (mammals) if it enters into their blood stream. Other source of transmission of this disease are contaminated blood transfusion, transplantation of organ for carrier donor, eating food that contains such parasite and vertical transmission is also possible in case of chagas disease.
Benznidazole is anti-parasitic drug that belongs to a medicinal class known as nitroimidazole. It works by releasing radical species that binds with parasite DNA and damage it. This will decrease the proliferation parasite inside the blood and ultimately disease spread will be reduce.
Benznidazole Side effects
According to health authorities following side effects were observed during clinical of this drug.
- Abdominal Pain
- Weight loss
- Loss of appetite
US FDA approved benznidazole for the treatment of Chagas disease in pediatric patients having age 2 to 12 years. Breastfeeding is not recommended during administration of benznidazole. This drug may interact with disulfiram so, there must be a gap of 2 weeks between these two therapies to avoid undesirable effects.